Valneva (VLAp)

Currency in EUR
2.635
0.000(0.00%)
Closed·
VLAp Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
VLAp is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.6352.635
52 wk Range
1.8523.425
Key Statistics
Bid/Ask
1.89 / 2.622
Prev. Close
2.635
Open
2.635
Day's Range
2.635-2.635
52 wk Range
1.852-3.425
Volume
155
Average Volume (3m)
1.47K
1-Year Change
-21.81%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VLAp Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Valneva News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.

Employees
713
Market
France

Compare VLAp to Peers and Sector

Metrics to compare
VLAp
Peers
Sector
Relationship
P/E Ratio
−6.9x−2.5x−0.5x
PEG Ratio
0.040.030.00
Price/Book
3.2x1.2x2.6x
Price / LTM Sales
3.0x4.5x3.2x
Upside (Analyst Target)
-153.7%41.7%
Fair Value Upside
Unlock9.8%6.1%Unlock

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.06 / -0.0957
Revenue / Forecast
49.20M / 41.80M
EPS Revisions
Last 90 days

VLAp Income Statement

People Also Watch

89.42
TEPRF
+1.71%
22.25
STMPA
-1.11%
240.10
TCFP
+0.80%
171.68
AIRP
-0.71%
249.70
ESLX
+1.01%

FAQ

What Stock Exchange Does Valneva Trade On?

Valneva is listed and trades on the BATS Europe stock exchange.

What Is the Stock Symbol for Valneva?

The stock symbol for Valneva is "VLAp."

What Is the Valneva Market Cap?

As of today, Valneva market cap is 550.67M.

What Is Valneva's Earnings Per Share (TTM)?

The Valneva EPS (TTM) is -0.54.

When Is the Next Valneva Earnings Date?

Valneva will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is VLAp a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Valneva Stock Split?

Valneva has split 0 times.

How Many Employees Does Valneva Have?

Valneva has 713 employees.

What is the current trading status of Valneva (VLAp)?

As of 26 Jul 2025, Valneva (VLAp) is trading at a price of 2.64, with a previous close of 2.64. The stock has fluctuated within a day range of 2.64 to 2.64, while its 52-week range spans from 1.85 to 3.43.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.